Schonfeld Strategic Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-759,393	Closed	-$2.19M	–	2334
2023 Q3	$2.19M	Buy	759,393 +215,706	+40%	+$789K	0.02%	806
2023 Q2	$2.07M	Sell	543,687 -69,492	-11%	-$195K	0.02%	744
2023 Q1	$1.14M	Buy	613,179 +238,338	+64%	+$498K	0.01%	907
2022 Q4	$862K	Buy	374,841 +104,668	+39%	+$321K	0.01%	1230
2022 Q3	$870K	Buy	270,173 +12,249	+5%	+$39.8K	0.01%	1358
2022 Q2	$1.42M	Buy	+257,924	New	+$802K	0.01%	864
2021 Q3	–	Sell	-37,413	Closed	-$486K	–	2565
2021 Q2	$486K	Sell	37,413 -15,900	-30%	-$213K	0.01%	1218
2021 Q1	$822K	Buy	+53,313	New	+$1.26M	0.01%	969

Other funds holding GRCL

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Schonfeld Strategic Advisors's GRCL Position: Q4 2023 in Review

Schonfeld Strategic Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2023, closing a stake of 759,393 shares — an estimated $2.19M sold.

Schonfeld Strategic Advisors first reported a position in GRCL in Q1 2021 and held it in 8 quarters. The position peaked at $2.19M in Q3 2023. 63 funds tracked by Wall St. Rank hold GRCL as of Q4 2023.

Schonfeld Strategic Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 759,393 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2023, an estimated $2.19M.
Schonfeld Strategic Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 8 quarters.
Schonfeld Strategic Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $2.19M in Q3 2023.
63 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.